Lynparza (Olaparib), First Treatment Approved for Breast Cancer Caused by Specific Gene Mutation

FRIDAY, Jan. 12, 2018 — Lynparza (olaparib) has been approved by the U.S. Food and Drug Administration to treat spreading breast cancer caused by a BRCA gene mutation.
The drug is among a class called poly ADP-ribose polymerase (PARP) inhibitors,…
Source: Topamax